164 related articles for article (PubMed ID: 37653737)
21. Short-term response might influence the treatment-related benefit of adjuvant chemotherapy after concurrent chemoradiotherapy for esophageal squamous cell carcinoma patients.
Liu A; Wang Y; Wang X; Zhu L; Nie Y; Li M
Radiat Oncol; 2021 Oct; 16(1):195. PubMed ID: 34600574
[TBL] [Abstract][Full Text] [Related]
22. A Real-World Data Study to Evaluate Treatment Patterns, Clinical Characteristics and Survival Outcomes for First- and Second-Line Treatment in Locally Advanced and Metastatic Urothelial Cancer Patients in Germany.
Niegisch G; Gerullis H; Lin SW; Pavlova J; Gondos A; Rudolph A; Haas G; Hennies N; Kramer MW
J Cancer; 2018; 9(8):1337-1348. PubMed ID: 29721042
[No Abstract] [Full Text] [Related]
23. Definite intensity-modulated radiotherapy with concurrent chemotherapy more than 4 cycles improved survival for patients with locally-advanced or inoperable esophageal squamous cell carcinoma.
Hsieh HY; Hsu CP; Yeh HL; Chuang CY; Lin JF; Chang CF
Kaohsiung J Med Sci; 2018 May; 34(5):281-289. PubMed ID: 29699635
[TBL] [Abstract][Full Text] [Related]
24. Paclitaxel and cisplatin combined with concurrent involved-field irradiation in definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: a phase II clinical trial.
Li H; Fang Y; Gu D; Du M; Zhang Z; Sun L; Zhou G; Ye J
Radiat Oncol; 2022 Jun; 17(1):105. PubMed ID: 35681233
[TBL] [Abstract][Full Text] [Related]
25. With or without consolidation chemotherapy using cisplatin/5-FU after concurrent chemoradiotherapy in stage II-III squamous cell carcinoma of the esophagus: A propensity score-matched analysis.
Chen Y; Guo L; Cheng X; Wang J; Zhang Y; Wang Y; Ke S; Shi W
Radiother Oncol; 2018 Oct; 129(1):154-160. PubMed ID: 29122362
[TBL] [Abstract][Full Text] [Related]
26. The crucial role of blood VEGF kinetics in patients with locally advanced esophageal squamous cell carcinoma receiving curative concurrent chemoradiotherapy.
Chen YH; Lu HI; Lo CM; Wang YM; Chou SY; Hsiao CC; Huang CC; Shih LH; Chen SW; Li SH
BMC Cancer; 2018 Aug; 18(1):837. PubMed ID: 30126380
[TBL] [Abstract][Full Text] [Related]
27. A study of concurrent chemoradiotherapy with weekly docetaxel and cisplatin for advanced esophageal squamous cell carcinoma with T4 and/or M1 lymph node metastasis or locoregional recurrence.
Liu Q; Xia Y; Chen Y; Zhang J; Deng J; Zhao K
Radiat Oncol; 2020 Apr; 15(1):75. PubMed ID: 32268925
[TBL] [Abstract][Full Text] [Related]
28. Esophageal stenosis and the Glasgow Prognostic Score as independent factors of poor prognosis for patients with locally advanced unresectable esophageal cancer treated with chemoradiotherapy (exploratory analysis of JCOG0303).
Okuno T; Wakabayashi M; Kato K; Shinoda M; Katayama H; Igaki H; Tsubosa Y; Kojima T; Okabe H; Kimura Y; Kawano T; Kosugi S; Toh Y; Kato H; Nakamura K; Fukuda H; Ishikura S; Ando N; Kitagawa Y;
Int J Clin Oncol; 2017 Dec; 22(6):1042-1049. PubMed ID: 28717855
[TBL] [Abstract][Full Text] [Related]
29. A phase-II/III randomized controlled trial of adjuvant radiotherapy or concurrent chemoradiotherapy after surgery versus surgery alone in patients with stage-IIB/III esophageal squamous cell carcinoma.
Ni W; Yu S; Zhang W; Xiao Z; Zhou Z; Chen D; Feng Q; Liang J; Lv J; Gao S; Mao Y; Xue Q; Sun K; Liu X; Fang D; Li J; Wang D
BMC Cancer; 2020 Feb; 20(1):130. PubMed ID: 32070309
[TBL] [Abstract][Full Text] [Related]
30. Comparison of paclitaxel in combination with cisplatin (TP), carboplatin (TC) or fluorouracil (TF) concurrent with radiotherapy for patients with local advanced oesophageal squamous cell carcinoma: a three-arm phase III randomized trial (ESO-Shanghai 2).
Ai D; Chen Y; Liu Q; Zhang J; Deng J; Zhu H; Ren W; Zheng X; Li Y; Wei S; Ye J; Zhou J; Lin Q; Luo H; Cao J; Li J; Huang G; Wu K; Fan M; Yang H; Zhu Z; Zhao W; Li L; Fan J; Badakhshi H; Zhao K
BMJ Open; 2018 Oct; 8(10):e020785. PubMed ID: 30344165
[TBL] [Abstract][Full Text] [Related]
31. The Benefits of Docetaxel Plus Cisplatin and 5-Fluorouracil Induction Therapy in Conversion to Curative Treatment for Locally Advanced Esophageal Squamous Cell Carcinoma.
Takeuchi M; Kawakubo H; Mayanagi S; Yoshida K; Irino T; Fukuda K; Nakamura R; Wada N; Takeuchi H; Kitagawa Y
World J Surg; 2019 Aug; 43(8):2006-2015. PubMed ID: 30972432
[TBL] [Abstract][Full Text] [Related]
32. A randomized phase 3 trial comparing paclitaxel plus 5-fluorouracil versus cisplatin plus 5-fluorouracil in Chemoradiotherapy for locally advanced esophageal carcinoma-the ESO-shanghai 1 trial protocol.
Chen Y; Zhu Z; Zhao W; Li L; Ye J; Wu C; Tang H; Lin Q; Li J; Xia Y; Li Y; Zhou J; Zhao K
Radiat Oncol; 2018 Feb; 13(1):33. PubMed ID: 29482649
[TBL] [Abstract][Full Text] [Related]
33. Concurrent chemoradiotherapy with S-1 compared with concurrent chemoradiotherapy with docetaxel and cisplatin for locally advanced esophageal squamous cell carcinoma.
Zhou XL; Yu CH; Wang WW; Ji FZ; Xiong YZ; Zhu WG; Tong YS
Radiat Oncol; 2021 May; 16(1):94. PubMed ID: 34039375
[TBL] [Abstract][Full Text] [Related]
34. Long-term results of concurrent chemoradiotherapy with daily-low-dose continuous infusion of 5-fluorouracil and cisplatin (LDFP) for Stage I-II esophageal carcinoma.
Kumabe A; Fukada J; Kota R; Koike N; Shiraishi Y; Seki S; Yoshida K; Kitagawa Y; Shigematsu N
Dis Esophagus; 2018 Apr; 31(4):. PubMed ID: 29228166
[TBL] [Abstract][Full Text] [Related]
35. Intensity-modulated radiotherapy combined with paclitaxel and platinum treatment regimens in locally advanced esophageal squamous cell carcinoma.
Chen J; Su T; Lin Y; Wang B; Li J; Pan J; Chen C
Clin Transl Oncol; 2018 Mar; 20(3):411-419. PubMed ID: 28779422
[TBL] [Abstract][Full Text] [Related]
36. Safety and efficacy of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in neoadjuvant chemoradiotherapy for patients with locally advanced esophageal carcinoma: a retrospective study.
Jiang L; Zhu J; Chen X; Wang Y; Wu L; Wan G; Han Y; Leng X; Peng L; Wang Q
Radiat Oncol; 2022 Dec; 17(1):218. PubMed ID: 36585731
[TBL] [Abstract][Full Text] [Related]
37. A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma.
Satake H; Tahara M; Mochizuki S; Kato K; Hara H; Yokota T; Kiyota N; Kii T; Chin K; Zenda S; Kojima T; Bando H; Yamazaki T; Iwasa S; Honma Y; Hamauchi S; Tsushima T; Ohtsu A
Cancer Chemother Pharmacol; 2016 Jul; 78(1):91-9. PubMed ID: 27193097
[TBL] [Abstract][Full Text] [Related]
38. Salvage concurrent radio-chemotherapy for post-operative local recurrence of squamous-cell esophageal cancer.
Zhang J; Peng F; Li N; Liu Y; Xu Y; Zhou L; Wang J; Zhu J; Huang M; Gong Y
Radiat Oncol; 2012 Jun; 7():93. PubMed ID: 22713587
[TBL] [Abstract][Full Text] [Related]
39. Durvalumab and tremelimumab with definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.
Park S; Oh D; Choi YL; Chi SA; Kim K; Ahn MJ; Sun JM
Cancer; 2022 Jun; 128(11):2148-2158. PubMed ID: 35319779
[TBL] [Abstract][Full Text] [Related]
40. Correlation of plasma miR-21 and miR-93 with radiotherapy and chemotherapy efficacy and prognosis in patients with esophageal squamous cell carcinoma.
Wang WT; Guo CQ; Cui GH; Zhao S
World J Gastroenterol; 2019 Oct; 25(37):5604-5618. PubMed ID: 31602161
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
